Allopurinol News and Research

RSS
Ardea Biosciences' revenues total $8.3M for three months ended December 31, 2009

Ardea Biosciences' revenues total $8.3M for three months ended December 31, 2009

Positive results from Ardea Biosciences' ongoing drug-drug interaction study of RDEA594 and febuxostat

Positive results from Ardea Biosciences' ongoing drug-drug interaction study of RDEA594 and febuxostat

On-going Phase 2b study conducted by Roche of ITMN-191 modified

On-going Phase 2b study conducted by Roche of ITMN-191 modified

Menarini granted exclusive European licence rights to Ipsen's Adenuric

Menarini granted exclusive European licence rights to Ipsen's Adenuric

Data on ULORIC treatment for gout flares presented at the 73rd American College of Rheumatology meeting

Data on ULORIC treatment for gout flares presented at the 73rd American College of Rheumatology meeting

URL Pharma's Colcrys approved by FDA for prevention of gout flares

URL Pharma's Colcrys approved by FDA for prevention of gout flares

Ardea Biosciences reports results of RDEA594 Phase 2a study for hyperuricemia and gout

Ardea Biosciences reports results of RDEA594 Phase 2a study for hyperuricemia and gout

CONFIRMS trial demonstrates efficacy of ULORIC for treating hyperuricemia in patients with gout

CONFIRMS trial demonstrates efficacy of ULORIC for treating hyperuricemia in patients with gout

FDA grants marketing approval for Elitek

FDA grants marketing approval for Elitek

Ardea's to present its hyperuricemia canditate study results at the ACR/ARHP Scientific Meeting

Ardea's to present its hyperuricemia canditate study results at the ACR/ARHP Scientific Meeting

Research study links high-fructose diet to increased blood pressure in men

Research study links high-fructose diet to increased blood pressure in men

Ardea Biosciences announces positive results from a phase 1 study of lead candidate for hyperuricemia and gout

Ardea Biosciences announces positive results from a phase 1 study of lead candidate for hyperuricemia and gout

Pegloticase BLA filing accepted for priority review by FDA

Pegloticase BLA filing accepted for priority review by FDA

Trial shows Elitek significantly reduces plasma uric acid levels versus Allopurinol in adults with hematologic cancers at risk for tumor Lysis syndrome

Trial shows Elitek significantly reduces plasma uric acid levels versus Allopurinol in adults with hematologic cancers at risk for tumor Lysis syndrome

Safety and efficacy of febuxostat for gout examined

Safety and efficacy of febuxostat for gout examined

New gout drug offers hope for those who have exhausted treatment options

New gout drug offers hope for those who have exhausted treatment options

Mini-strokes linked to uric acid levels

Mini-strokes linked to uric acid levels

High uric acid levels indicate risk for cognitive problems in old age

High uric acid levels indicate risk for cognitive problems in old age

Allopurinol, a common gout drug may also offer some protection against colorectal cancer

Allopurinol, a common gout drug may also offer some protection against colorectal cancer

Gene of immune system linked to severe adverse drug reaction called Stevens-Johnson syndrome (SJS)

Gene of immune system linked to severe adverse drug reaction called Stevens-Johnson syndrome (SJS)